Application of ginseng, ganoderma lucidum and liquorice composition in preparation of product for treating new crown growth and / or relieving new crown growth symptom, related product and preparation method of related product
By using Ganoderma lucidum, ginseng genus medicinal materials, Cordyceps sinensis and other ingredients in the ginseng Lingcao composition, it has solved the problem of poor treatment effect and storage stability of the symptoms of new crown in the existing technology, and achieved the goal of achieving the A Chinese medicine composition with a good taste and a long storage period has significantly improved the symptoms of new crown.
Patent Information
- Application Number
- CN202410830649.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-25
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-06-25
AI Technical Summary
The prior art has not yet provided a traditional Chinese medicine composition that has a better taste, a longer storage period, and a better therapeutic effect for long-term COVID-19 symptoms.
Provide a composition of ginseng Lingcao, including Ganoderma lucidum, ginseng genus genus of the Pentaga family, Cordyceps sinensis, rose and other ingredients. The oral solution of ginseng Lingcao is obtained by decoction and concentration, and maltitol, cyclodextrin and American ginseng essence are added. Prepare into good oral liquid dosage form.
Shenlingcao Oral Liquid has a good taste and a long storage period, which significantly improves symptoms of new crown such as fatigue, insomnia, anxiety, itchy throat, chest pain, etc. It is an effective product for treating new crown.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of traditional Chinese medicine preparations, and relates to the use of a ginseng herb composition in the preparation of products for treating COVID-19 and / or alleviating the symptoms of COVID-19, related products and their preparation methods. Background Art
[0002] According to the World Health Organization (WHO), long COVID refers to continued or new symptoms that continue or appear three months after the initial SARS-CoV-2 infection, including fatigue, shortness of breath, and cognitive dysfunction. Ho et al. pointed out in the article "Long COVID and its management" (Int. J. Biol. Sci. 2022; 18 (12): 4768-4780) that up to 70% of people who have recovered from COVID-19 infection will experience long-term clinical symptoms. These recurring symptoms may last for weeks or months, seriously reducing the quality of life of people who have recovered from COVID-19 infection.
[0003] Chinese patent application 202311182546.9 discloses a Cordyceps militaris composition for treating COVID-19 sequelae and its preparation method, which relates to the field of treating COVID-19 sequelae. The composition is made of the following raw materials in parts by weight: 14-23 parts of Cordyceps militaris, 11-16 parts of Frosted Mulberry Leaves, 7-14 parts of Loquat Leaves, 12-15 parts of Angelica Sinensis, 3-6 parts of Cistanche deserticola, 6-9 parts of Astragalus, 3-7 parts of Lilium, 7-11 parts of Ginseng, 11-14 parts of Asarum, 4-9 parts of Scutellaria, 2-4 parts of Schisandrae Chinensis, and 2-7 parts of Chinese Yam. This composition is added with Cordyceps militaris and Frosted Mulberry Leaves, which has the effects of clearing the lungs and moisturizing dryness, resolving phlegm and activating blood circulation, and nourishing qi and yin. The composition can significantly improve the tissue structure of the lungs, effectively treat COVID-19 sequelae, and improve the quality of life of patients.
[0004] Chinese patent application 202310516853.X discloses a Chinese medicine preparation for conditioning body functions after recovery from COVID-19 and a method for preparing its atomized liquid. The prescription includes ginseng, Poria cocos, Eucommia ulmoides leaves, raspberry, Patchouli, Angelica dahurica, Perilla leaves, mulberry leaves, dandelion, and dried orange peel. The prescription takes into account patients with yin deficiency, qi deficiency, and deficiency heat. Regulating body functions after recovery from COVID-19 can play a role in rapid recovery. By taking the decoction and adjusting the body's own lifestyle, the body can be strengthened and the resistance can be improved, thereby resisting evil spirits. This solves the problem of "preventing changes after the disease" and "preventing recurrence after recovery" after recovery from COVID-19.
[0005] Chinese patent application 201210184710.5 discloses a composition for improving the toxic and side effects of chemotherapy in patients with malignant tumors and its application. It includes 5-200 parts of Ganoderma lucidum, 5-150 parts of American ginseng or ginseng, 1-90 parts of fermented Cordyceps sinensis powder and / or 1-120 parts of Cordyceps sinensis, or a composition composed of water and / or alcohol extracts of the above raw materials as active ingredients in the preparation of health care products or medicines or products for improving the toxic and side effects of chemotherapy in patients with malignant tumors. However, the technology does not provide a Chinese medicine composition with better taste, longer storage period, and better efficacy against the symptoms of long-term new coronary pneumonia. Summary of the invention
[0006] In view of this, and in view of the problem that the prior art has not yet provided a traditional Chinese medicine composition with better taste, longer storage period and better efficacy for the symptoms of COVID-19, the purpose of the present invention is to provide a use of a ginseng herb composition in the preparation of treatments for COVID-19 and / or relief of the symptoms of COVID-19, related products and their preparation methods.
[0007] To achieve the above-mentioned purpose of the invention, on the one hand, the present invention provides a use of a ginseng grass composition in preparing a product for treating COVID-19 and / or alleviating the symptoms of COVID-19, wherein the raw materials of the ginseng grass composition include the following components: Ganoderma lucidum, Araliaceae ginseng herbs, cordyceps, roses; Wherein, the Araliaceae Panax genus medicinal material is one or both of ginseng and American ginseng; The cordyceps is selected from one or both of fermented cordyceps powder and cordyceps sinensis.
[0008] Preferably, the long COVID symptoms include at least one of: physical and mental fatigue, insomnia, decreased sleep quality, decreased physical function, decreased social function, body pain, anxiety, poor heart rate variability, brain fog, chest pain, and itchy throat.
[0009] Preferably, the raw materials of the ginseng grass composition also include maltitol, cyclodextrin and American ginseng essence.
[0010] Preferably, among the raw materials of the ginseng grass composition, The ganoderma lucidum is one or more of ganoderma lucidum fruiting bodies, ganoderma lucidum decoction pieces, and ganoderma lucidum spore powder; The cyclodextrin is at least one of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin; The cordyceps is fermented cordyceps powder.
[0011] More preferably, in the raw materials of the Shenlingcao composition, the Araliaceae Panax genus medicinal material is a mixture of ginseng and American ginseng; and the cyclodextrin is a mixture of β-cyclodextrin and γ-cyclodextrin.
[0012] More preferably, in the raw materials of the ginseng grass composition, the American ginseng essence includes the following ingredients: Ginseng oil, p-isopropyl-2-methylphenylpropionaldehyde, gamma-nonalactone, ethyl maltol, 3-methylbutyl butyrate, coumarin, Span-80 and glycerin.
[0013] Preferably, the raw materials of the ginseng grass composition include the following components by mass: 20-120 parts of ganoderma lucidum, 10-90 parts of medicinal materials of Panax genus of Araliaceae, 3-90 parts of cordyceps, 10-60 parts of rose, 1-80 parts of maltitol, 1-30 parts of cyclodextrin and 0.1-2 parts of American ginseng essence.
[0014] More preferably, the raw materials of the ginseng grass composition include the following components by mass: 30-110 parts of ganoderma lucidum, 10-90 parts of medicinal materials of genus Panax of Araliaceae, 25-55 parts of cordyceps, 10-35 parts of rose, 7-19 parts of maltitol, 11-23 parts of cyclodextrin and 0.5-2 parts of American ginseng essence.
[0015] More preferably, the raw materials of the ginseng grass composition include the following components by mass: 50-90 parts of ganoderma lucidum, 30-70 parts of medicinal materials of genus Panax of Araliaceae, 35-45 parts of cordyceps, 15-25 parts of rose, 10-16 parts of maltitol, 14-20 parts of cyclodextrin and 0.9-1.6 parts of American ginseng essence.
[0016] Most preferably, the raw materials of the ginseng grass composition include the following components by mass: 70 parts of ganoderma lucidum, 50 parts of medicinal materials of Panax genus of Araliaceae, 40 parts of cordyceps, 20 parts of rose flowers, 13 parts of maltitol, 17 parts of cyclodextrin and 1 part of American ginseng essence.
[0017] Further preferably, among the raw materials of the ginseng and herb composition, the Ganoderma lucidum is a mixture of Ganoderma lucidum decoction pieces and Ganoderma lucidum spore powder in a mass ratio of 2-4:1-3; the Araliaceae Panax genus medicinal material is a mixture of American ginseng and ginseng in a mass ratio of 1-5:5-9.
[0018] Most preferably, among the raw materials of the ginseng and herb composition, the Ganoderma lucidum is a mixture of Ganoderma lucidum decoction pieces and Ganoderma lucidum spore powder in a mass ratio of 3:2; and the Araliaceae Panax genus medicinal material is a mixture of American ginseng and ginseng in a mass ratio of 3:7.
[0019] Further preferably, in the raw materials of the ginseng grass composition, the cyclodextrin is a mixture of β-cyclodextrin and γ-cyclodextrin in a mass ratio of 2-3.5:1.5-3.
[0020] Most preferably, among the raw materials of the ginseng grass composition, the cyclodextrin is a mixture of β-cyclodextrin and γ-cyclodextrin in a mass ratio of 2.75:2.25.
[0021] More preferably, in the raw materials of the ginseng grass composition, the American ginseng essence includes the following components by mass: 35-45 parts of ginseng oil, 3-7 parts of p-isopropyl-2-methylphenylpropionaldehyde, 2-6 parts of γ-nonalactone, 1 part of ethyl maltol, 8-12 parts of 3-methylbutyl butyrate, 4-8 parts of coumarin, 1-5 parts of Span-80 and 3-6 parts of glycerol.
[0022] More preferably, in the raw materials of the ginseng grass composition, the American ginseng essence includes the following components by mass: 40 parts of ginseng oil, 5 parts of p-isopropyl-2-methylphenylpropionaldehyde, 4 parts of γ-nonalactone, 1 part of ethyl maltol, 10 parts of 3-methylbutyl butyrate, 6 parts of coumarin, 3 parts of Span-80 and 5 parts of glycerol.
[0023] The dosage form of the ginseng grass composition includes but is not limited to pills, tablets, powders, granules, oral liquids, lozenges, ointments, and the like.
[0024] More preferably, the ginseng herb composition is ginseng herb oral liquid.
[0025] On the other hand, the present invention provides a ginseng grass composition for the above-mentioned use.
[0026] In another aspect, the present invention provides a method for preparing the Shenlingcao oral liquid described in the above-mentioned use, characterized in that it comprises the following steps: (1) Take Ganoderma lucidum, Panax ginseng of the Araliaceae family, Cordyceps sinensis and rose, decoct them 2-3 times with 8-12 times the weight of water, collect the filtrate, concentrate it, and centrifuge it to obtain the supernatant; (2) The supernatant obtained in step (1), maltitol, cyclodextrin, American ginseng essence and water are mixed to obtain Shenlingcao oral liquid.
[0027] Preferably, the volume ratio of the total mass of the Ganoderma lucidum, the Araliaceae Panax genus medicinal materials, Cordyceps sinensis and rose in step (1) to the prepared Ganoderma lucidum oral liquid is 0.5-4:20 (g:mL).
[0028] In yet another aspect, the present invention provides a ginseng herb oral liquid prepared by the above preparation method.
[0029] Compared with the prior art, the present invention has the following beneficial effects: (1) The present invention provides a ginseng grass composition, which can be used to prepare a ginseng grass oral liquid. The ginseng grass oral liquid has a good taste and maintains stable quality during a long storage period.
[0030] (2) The above-mentioned Shenlingcao oral liquid provided by the present invention can significantly improve the symptoms of COVID-19 including fatigue, insomnia, brain fog, anxiety, itchy throat, chest pain, etc., and can be used as an effective product for the treatment of COVID-19.
[0031] (3) The present invention also provides a method for preparing the above-mentioned Shenlingcao oral liquid. The preparation method is simple and easy to implement and can be easily promoted. DETAILED DESCRIPTION
[0032] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.
[0033] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.
[0034] In the following examples of the present invention, the fermented Cordyceps sinensis powder used is preferably fermented Cordyceps sinensis powder Cs-4.
[0035] The following Examples 1-5 provide a ginseng grass composition, the components and mass proportions of which are shown in the following table (unit: mass parts).
[0036]
[0037] The following Examples 6-11 provide a ginseng grass composition, the components and mass proportions of which are shown in the following table (unit: mass parts).
[0038]
[0039] In Example 1-11, the American ginseng essence is mixed by the following substances in parts by mass: 40 parts of ginseng oil, 5 parts of p-isopropyl-2-methylphenylpropionaldehyde, 4 parts of γ-nonalactone, 1 part of ethyl maltol, 10 parts of 3-methylbutyl butyrate, 6 parts of coumarin, 3 parts of Span-80 and 5 parts of glycerol.
[0040] Compared with Example 1, Example 12 and Example 13 differ in that the material ratio of the American ginseng essence is different, and the types and mass parts of the other components and the total amount of the American ginseng essence are the same as those of Example 1. The components and mass ratios of the American ginseng essence of Example 1, Example 12, and Example 13 are shown in the following table (unit: mass parts).
[0041]
[0042] The following Examples 14-20 provide a ginseng grass composition, the components and mass proportions of which are shown in the following table (unit: mass parts, "-" means that the component is not contained).
[0043]
[0044] Similar to Example 1-11, in Example 14-20, the American ginseng essence is mixed by the following substances in parts by mass: 40 parts of ginseng oil, 5 parts of p-isopropyl-2-methylphenylpropionaldehyde, 4 parts of γ-nonalactone, 1 part of ethyl maltol, 10 parts of 3-methylbutyl butyrate, 6 parts of coumarin, 3 parts of Span-80 and 5 parts of glycerol.
[0045] Embodiment 21 Compared with Example 1, the fermented Cordyceps sinensis powder was replaced with Cordyceps sinensis of equal mass, and the rest were the same.
[0046] The following Examples 22-23 provide a ginseng grass composition, the components and mass proportions of which are shown in the following table (unit: mass parts, “-” means that the component is not contained).
[0047]
[0048] Similar to Example 1-11, in Example 22-23, the American ginseng essence is mixed by the following substances in parts by mass: 40 parts of ginseng oil, 5 parts of p-isopropyl-2-methylphenylpropionaldehyde, 4 parts of γ-nonalactone, 1 part of ethyl maltol, 10 parts of 3-methylbutyl butyrate, 6 parts of coumarin, 3 parts of Span-80 and 5 parts of glycerol.
[0049] Preparation Example 1 Preparation method of Shenlingcao oral liquid: Take the formula amount of Ganoderma lucidum, Araliaceae Panax ginseng medicinal materials, fermented Cordyceps powder / Cordyceps sinensis and rose, crush them with a traditional Chinese medicine grinder, decoct them 3 times with 10 times the mass of water, filter, collect the filtrate after each decoction, concentrate to a density of 1.02-1.05, centrifuge at 5000rpm for 2 minutes, and take the supernatant. The obtained supernatant, the formula amount of maltitol, cyclodextrin, and American ginseng flavor are mixed, and an appropriate amount of purified water is added so that the total mass of Ganoderma lucidum, Araliaceae Panax ginseng medicinal materials, fermented Cordyceps powder and rose to the volume of the Shenlingcao oral liquid is 1:20 (g:mL). Further, the obtained Shenlingcao oral liquid is canned and pasteurized in a suitable volume to form a Shenlingcao oral liquid product.
[0050] By adopting the above method, according to the ginseng grass composition provided in Examples 1-23, ginseng grass oral liquids can be prepared, which are named oral liquids 1-23 respectively.
[0051] Comparative Example 1 Compared with Example 1, the cyclodextrin used was changed to maltodextrin (DE value 16.5-19.5) of equal mass, and the rest were the same.
[0052] Comparative Example 2 Compared with Example 1, the rose flowers used were changed to roselle flowers of equal mass, and the rest were the same.
[0053] Comparative Example 3 Compared with Example 1, the American ginseng essence used is replaced by the American ginseng essence provided in Example 1 of Chinese patent application 201710287898.9 of equal quality, and the rest are the same.
[0054] Specifically, the American ginseng essence is composed of the following components in percentage by mass: 10% American ginseng extract (ethanol reflux extraction), 1% diacetyl, 0.3% linalool, 0.5% methyl cinnamate, 0.2% myrcene, 1% clove oil, 87% caprylic / capric glyceride.
[0055] Comparative Example 4 Compared with Example 1, the medicinal material of the genus Panax of the Araliaceae family was changed to Radix Pseudostellariae of equal quality, and the rest were the same.
[0056] Comparative Example 5 Compared with Example 1, the maltitol used was replaced by mannose of equal mass, and the rest were the same.
[0057] Preparation Example 2 Preparation method of Shenlingcao oral liquid: Take the formula amount of Ganoderma lucidum, Panax ginseng medicinal materials of Araliaceae (Comparative Example 4 is Pseudostellaria heterophylla), fermented Cordyceps powder and rose (Comparative Example 2 is Roselle), crush them with a Chinese medicine grinder, decoct them 3 times with 10 times the mass of water, filter, collect the filtrate after each decoction, concentrate to a density of 1.02-1.05, centrifuge at 5000rpm for 2 minutes, and take the supernatant. The obtained supernatant, the formula amount of maltitol (Comparative Example 5 is lactitol), cyclodextrin (Comparative Example 1 is dextrin), and American ginseng essence are mixed, and an appropriate amount of purified water is added so that the total mass of the Ganoderma lucidum, Panax ginseng medicinal materials of Araliaceae (Comparative Example 4 is Pseudostellaria heterophylla), fermented Cordyceps powder and rose (Comparative Example 2 is Roselle) used is 1:20 (g:mL) to the volume of the Shenlingcao oral liquid. Further, the obtained Shenlingcao oral liquid is canned and pasteurized in a suitable volume to form a Shenlingcao oral liquid product.
[0058] By adopting the above method, according to the Shenlingcao compositions provided in Comparative Examples 1-5, Shenlingcao oral liquids can be prepared, which are named oral liquids C1-C5 respectively.
[0059] Effect evaluation 1. Sensory evaluation of Shenlingcao oral liquid after being placed at 0℃, 25℃ and 45℃ for 1 day, 20 days and 40 days respectively.
[0060] The oral liquids 1-23 obtained in Preparation Example 1 and the oral liquids C1-C5 obtained in Preparation Example 2 were placed in the environment of 0°C, 25°C and 45°C for 1 day, 20 days and 40 days respectively, and then the sensory evaluation test was carried out. 10 trained volunteers aged 25-50 were selected, and they were asked to taste the oral liquids 1-23 obtained in Preparation Example 1 and the oral liquids C1-C5 obtained in Preparation Example 2, and then the appearance, taste and mouthfeel of the above oral liquids were scored (the scoring range was arbitrarily between 0-10 points), and the average values were taken to obtain the sensory evaluation test results. The specific scoring judgment basis is shown in the following table:
[0061] The appearance evaluation scores of Shenlingcao oral liquid after being placed at 25°C for 1 day, 20 days and 40 days are shown in the following table:
[0062] The appearance evaluation scores of Shenlingcao oral liquid after being placed at 0°C for 1 day, 20 days and 40 days are shown in the following table:
[0063] The appearance evaluation scores of Shenlingcao oral liquid after being placed at 40°C for 1 day, 20 days and 40 days are shown in the following table:
[0064] It can be seen that the appearance evaluation scores of the oral liquid 1-23 obtained in Preparation Example 1 after being stored at 0°C, 25°C, and 40°C for 1 day, 20 days, and 40 days, respectively, are generally higher than the appearance evaluation scores of the oral liquids C1 and C5 obtained in Preparation Example 2. Specifically, in oral liquid C1, maltodextrin is used to replace cyclodextrin, and in oral liquid C5, mannose is used to replace maltitol. The appearance scores after storage at 0°C, 25°C, and 40°C for 40 days are significantly lower than those of oral liquids 1-23. This shows that the types of the two excipients, cyclodextrin and maltitol, play an important role in the appearance stability of the Shenlingcao oral liquid, and it cannot be achieved by arbitrarily selecting the types of excipients.
[0065] The taste evaluation scores of Shenlingcao oral liquid after being placed at 25°C for 1 day, 20 days and 40 days are shown in the following table:
[0066] The taste evaluation scores of Shenlingcao oral liquid after being placed at 0°C for 1 day, 20 days and 40 days are shown in the following table:
[0067] The taste evaluation scores of Shenlingcao oral liquid after being placed at 40°C for 1 day, 20 days and 40 days are shown in the following table:
[0068] It can be seen that the taste evaluation scores of oral liquids 1-23 obtained in Preparation Example 1 after being stored at 0°C, 25°C, and 40°C for 1 day, 20 days, and 40 days, respectively, are generally higher than the taste evaluation scores of oral liquids C1-C5 obtained in Preparation Example 2. Specifically, in oral liquid C1, maltodextrin is used to replace cyclodextrin; in oral liquid C2, roselle is used instead of rose; in oral liquid C3, different types of flavors provided by different prior arts are used; in oral liquid C4, Pseudostellaria chinensis is used to replace Panax ginseng medicinal materials; and in oral liquid C5, mannose is used to replace maltitol. After oral liquids C1-C5 are stored at 0°C, 25°C, and 40°C for 40 days, respectively, their taste scores are all lower than those of oral liquids 1-23. This indicates that the use of Araliaceae Panax medicinal materials, rose, and the types of cyclodextrin, maltitol and Pseudostellaria heterophylla essence in the Shenlingcao oral liquid provided by the present invention all have a significant effect on improving the taste evaluation of the Shenlingcao oral liquid, and this effect on improving the taste cannot be achieved by arbitrarily selecting the main ingredients or auxiliary ingredients.
[0069] The taste evaluation scores of Shenlingcao oral liquid after being placed at 25°C for 1 day, 20 days and 40 days are shown in the following table:
[0070] The taste evaluation scores of Shenlingcao oral liquid after being placed at 0°C for 1 day, 20 days and 40 days are shown in the following table:
[0071] The taste evaluation scores of Shenlingcao oral liquid after being placed at 40°C for 1 day, 20 days and 40 days are shown in the following table:
[0072] It can be seen that the taste evaluation scores of the oral liquid 1-23 obtained in Preparation Example 1 after being stored at 0°C, 25°C, and 40°C for 1 day, 20 days, and 40 days, respectively, are generally higher than the taste evaluation scores of the oral liquids C1 and C5 obtained in Preparation Example 2. Specifically, in oral liquid C1, maltodextrin is used to replace cyclodextrin, and in oral liquid C5, mannose is used to replace maltitol. The taste scores after storage at 0°C, 25°C, and 40°C for 40 days are significantly lower than those of oral liquids 1-23. This shows that the types of the two excipients, cyclodextrin and maltitol, play an important role in the taste stability of the Shenlingcao oral liquid, and it cannot be achieved by arbitrarily selecting the types of excipients.
[0073] 2. Experiment on the effect of Shenlingcao oral liquid on improving clinical symptoms of patients with COVID-19.
[0074] 2.1 Case selection Inclusion criteria: Adults aged 18-65 years; meet the diagnostic criteria for long COVID-19 released by the Centers for Disease Control and Prevention (CDC) in 2022: have been infected with SARS-CoV-2 and symptoms persisted for more than 4 weeks (calculated from the date of the first positive PCR / rapid test result); the Chalder Fatigue Scale binary score (0-11 points) is not less than 4 points.
[0075] Exclusion criteria: (1) Suffering from diseases that may cause chronic fatigue before contracting Covid-19, including but not limited to: a. Cardiovascular and cerebrovascular diseases, such as arrhythmia, heart failure, myocardial infarction and stroke.
[0076] b. Chronic lung diseases, such as chronic obstructive pulmonary disease, moderate to severe asthma.
[0077] c. Sleep apnea syndrome and narcolepsy.
[0078] d. Cognitive impairment, such as Alzheimer's disease and vascular dementia.
[0079] e. Have serious mental illness, such as severe depression, schizophrenia, and anorexia nervosa.
[0080] f. Untreated hypothyroidism.
[0081] g. Chronic liver and kidney diseases.
[0082] h.Tumor.
[0083] i. Immune deficiency.
[0084] (2) The patient is currently taking or needs to continue to take long-term medications that may affect the test results (including but not limited to: antibiotics, hormone drugs, analgesics, psychotropic drugs, intestinal flora regulating drugs, etc.).
[0085] (3) Severely obese people (body mass index (BMI) not less than 45).
[0086] (4) Alcohol or other drug addicts.
[0087] (5) Those who are allergic to Chinese medicine.
[0088] (6) Pregnant women, breastfeeding women, and women planning to become pregnant.
[0089] Elimination criteria: (1) Those who are found not to meet the inclusion criteria or meet the exclusion criteria after inclusion.
[0090] (2) Those who could not be contacted more than 30 days after randomization.
[0091] (3) Unauthorized use / acceptance of other therapeutic drugs or treatments that may affect the observed indicators.
[0092] 2.2 Treatment options Experimental samples: The oral solution 1 obtained in Preparation Example 1 was referred to as "Oral Solution 1 Group".
[0093] "Placebo group". The composition of the solution used in the placebo group: Each 100 mL of the placebo group solution contained 5 g of maltitol, 3.5 g of maltodextrin, 3 g of sucrose octaacetate, 1 g of caramel pigment, 1 g of American ginseng essence, and the remainder of purified water; the American ginseng essence was the same as the American ginseng essence used in Example 1.
[0094] Grouping: Simple random method was used. The random sequence was generated by an independent researcher using Random Allocation Software 2.0. The random number participants were allocated to oral solution group 1 or placebo group (a total of 152 people, 76 people in each group) at a ratio of 1:1. The grouping sequence will be stored in a light-proof sealed envelope and kept by the person in charge of the study. The drug production factory will generate a label based on the sequence number and stick it on the corresponding study drug. Each patient will be assigned a sequence number. Participants, researchers and data analysts will not know the grouping of participants until the end of the study.
[0095] Directions: After a 2-week screening period, each group was given oral solution, with a treatment period of 4 weeks and a follow-up period of 4 weeks. The medication method was oral, with a dosage of 200 mL per bottle, twice a day, 1 bottle each time.
[0096] Treatment course: The intervention period was 28 days, and the follow-up period was 28 days, for a total of 56 days.
[0097] 2.3 Observation items 1. Main outcome measure: Chalder fatigue scale The change in the Chalder Fatigue Scale (CFS-33) score (0-33 points) after four weeks of treatment compared with baseline.
[0098] The Chalder Fatigue Scale has 11 items in total, covering two dimensions: physical (7 items) and mental fatigue (4 items). It is evaluated using a 4-point Likert-type scoring method: 0 points means less than before, 1 point means the same symptoms as before, 2 points means slightly more severe than before, and 3 points means much more severe than before. The total score is 33 points. The higher the score of the respondent, the more severe the fatigue.
[0099] The specific contents of the Chalder Fatigue Scale are shown in the following table:
[0100] 2. Secondary outcome indicators (1) Changes in the Insomnia Severity Index (ISI) scores compared with baseline after four weeks of treatment and four weeks of follow-up.
[0101] The specific contents of the Insomnia Severity Scale are shown in the following table:
[0102] (2) Quality of life score SF-36 Changes in the SF-36 quality of life score compared with baseline scores after four weeks of treatment and after a four-week follow-up period.
[0103] The SF-36 scoring system consists of 36 questions, of which the second question is not included in the scoring, and 35 questions are condensed into 8 multi-item scales. (1) Physical function is a 10-item scale that covers the ability to cope with the physical demands of life, such as meeting personal needs, walking, and flexibility; (2) Role-physical is a four-item scale that assesses the degree to which physical abilities limit activities; (3) Bodily pain is a two-item scale that assesses the amount of pain perceived in the past 4 weeks and the degree to which pain interferes with normal work activities; (4) General health is a five-item scale that assesses general health; (5) Vitality is a four-item scale that assesses feelings of spirit, energy, and fatigue; (6) Social functioning (SF) is a two-item scale that assesses the degree and amount of time (if any) that physical health or emotional problems have interfered with family, friends, and other social interactions in the past 4 weeks; (7) Role-emotional (RE) is a three-item scale that assesses the degree to which emotional factors interfere with work or other activities (if any); (8) Mental health is a five-item scale that mainly assesses feelings of anxiety and depression.
[0104] The specific contents of the SF-36 quality of life rating scale are shown in the following table:
[0105] (3) Anxiety and Depression Scale Changes from baseline in the hospital anxiety and depression scale (HADS) after four weeks of treatment and a four-week follow-up period.
[0106] The specific contents of the HADS are shown in the following table:
[0107] (4) Self-assessment of COVID-19 symptoms Changes in long-term COVID-19 symptom scores after four weeks of treatment and follow-up compared with baseline scores. The survey items included brain fog (difficulty thinking or concentrating), itchy throat, and chest pain.
[0108] The specific contents of the self-assessment form are shown in the following table:
[0109] (5) Exploratory indicators: The last 20 people in the oral solution group 1 and the placebo group were selected as research subjects. Heart rate and sleep indicators (including total sleep time, light sleep time, deep sleep time and heart rate variability) were collected using wearable devices. The tests were performed in weeks 1 to 4 of the intervention period and weeks 1 to 4 of the subsequent follow-up period. The change rate of total sleep time compared with the baseline was calculated.
[0110] 2.4 Clinical Outcomes The results of the clinical experiments recorded in 2.3 (Chalder Fatigue Scale, Insomnia Severity Scale, Quality of Life Score SF-36, Anxiety and Depression Scale HADS, and Assessment of Self-Symptoms of Long-term COVID-19 (including itchy throat, chest pain, and brain fog)) are summarized as shown in the following table:
[0111] From the experimental results in the above table, it can be seen that for the symptoms of COVID-19 such as fatigue, insomnia, anxiety, decreased physical function, decreased social function, body pain, brain fog, itchy throat, chest pain, etc., the improvement effect brought by the oral liquid 1 group was significantly better than that of the placebo group, and the p values were all less than 0.05.
[0112] Summarize the test results of using wearable devices to collect heart rate and sleep indicators (including total sleep time, light sleep time, deep sleep time and heart rate variability) recorded in 2.3.
[0113] Among them, the change rate of total sleep duration compared with the baseline is shown in the following table:
[0114] The rate of change of light sleep duration compared to baseline is shown in the following table:
[0115] The rate of change of deep sleep duration compared to baseline is shown in the following table:
[0116] It can be seen that Shenlingcao oral liquid has the effect of significantly prolonging sleep time and improving sleep quality.
[0117] The effects of oral solution 1 and placebo on heart rate variability are shown in the following table:
[0118] It can be seen that the oral solution 1 group had a significant effect on improving heart rate variability compared with the placebo group.
[0119] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. Use of a ginseng grass composition in the preparation of a product for treating COVID-19 and / or alleviating the symptoms of COVID-19, It is characterized in that The raw materials of the ginseng grass composition include the following ingredients: Ganoderma lucidum, Araliaceae ginseng herbs, cordyceps, roses; Wherein, the Araliaceae Panax genus medicinal material is one or both of ginseng and American ginseng; The cordyceps is selected from one or both of fermented cordyceps powder and cordyceps sinensis.
2. The use according to claim 1, It is characterized in that The symptoms of long COVID include at least one of: physical and mental fatigue, insomnia, decreased sleep quality, decreased physical function, decreased social function, body pain, anxiety, poor heart rate variability, brain fog, chest pain, and itchy throat.
3. The use according to claim 1, It is characterized in that The raw materials of the ginseng grass composition also include maltitol, cyclodextrin and American ginseng essence.
4. The use according to claim 3, It is characterized in that Among the raw materials of the ginseng grass composition, The ganoderma lucidum is one or more of ganoderma lucidum fruiting bodies, ganoderma lucidum decoction pieces, and ganoderma lucidum spore powder; The cyclodextrin is at least one of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin; The cordyceps is fermented cordyceps powder.
5. The use according to claim 3, It is characterized in that Among the raw materials of the Shenlingcao composition, the Araliaceae Panax genus medicinal material is a mixture of ginseng and American ginseng; and the cyclodextrin is a mixture of β-cyclodextrin and γ-cyclodextrin.
6. The use according to claim 3, It is characterized in that Among the raw materials of the ginseng grass composition, the American ginseng essence includes the following ingredients: Ginseng oil, p-isopropyl-2-methylphenylpropionaldehyde, gamma-nonalactone, ethyl maltol, 3-methylbutyl butyrate, coumarin, Span-80 and glycerin.
7. The use according to any one of claims 3 to 6, It is characterized in that The raw materials of the ginseng grass composition include the following components by mass: 20-120 parts of ganoderma lucidum, 10-90 parts of medicinal materials of Panax genus of Araliaceae, 3-90 parts of cordyceps, 10-60 parts of rose, 1-80 parts of maltitol, 1-30 parts of cyclodextrin and 0.1-2 parts of American ginseng essence.
8. The use according to claim 7, It is characterized in that The raw materials of the ginseng grass composition include the following components by mass: 30-110 parts of ganoderma lucidum, 10-90 parts of medicinal materials of genus Panax of Araliaceae, 25-55 parts of cordyceps, 10-35 parts of rose, 7-19 parts of maltitol, 11-23 parts of cyclodextrin and 0.5-2 parts of American ginseng essence.
9. The use according to claim 8, It is characterized in that The raw materials of the ginseng grass composition include the following components by mass: 50-90 parts of ganoderma lucidum, 30-70 parts of medicinal materials of genus Panax of Araliaceae, 35-45 parts of cordyceps, 15-25 parts of rose, 10-16 parts of maltitol, 14-20 parts of cyclodextrin and 0.9-1.6 parts of American ginseng essence.
10. The use according to claim 9, It is characterized in that Among the raw materials of the ginseng and herb composition, the Ganoderma lucidum is a mixture of Ganoderma lucidum decoction pieces and Ganoderma lucidum spore powder in a mass ratio of 2-4:1-3; the Araliaceae Panax genus medicinal material is a mixture of American ginseng and ginseng in a mass ratio of 1-5:5-9.
11. The use according to claim 7, It is characterized in that Among the raw materials of the ginseng grass composition, the cyclodextrin is a mixture of β-cyclodextrin and γ-cyclodextrin in a mass ratio of 2-3.5:1.5-3.
12. The use according to claim 7, It is characterized in that Among the raw materials of the ginseng grass composition, the American ginseng essence includes the following components by mass: 35-45 parts of ginseng oil, 3-7 parts of p-isopropyl-2-methylphenylpropionaldehyde, 2-6 parts of γ-nonalactone, 1 part of ethyl maltol, 8-12 parts of 3-methylbutyl butyrate, 4-8 parts of coumarin, 1-5 parts of Span-80 and 3-6 parts of glycerol.
13. The use according to claim 12, It is characterized in that Among the raw materials of the ginseng grass composition, the American ginseng essence includes the following components by mass: 40 parts of ginseng oil, 5 parts of p-isopropyl-2-methylphenylpropionaldehyde, 4 parts of γ-nonalactone, 1 part of ethyl maltol, 10 parts of 3-methylbutyl butyrate, 6 parts of coumarin, 3 parts of Span-80 and 5 parts of glycerol.
14. The use according to claim 7, It is characterized in that The ginseng grass composition is a ginseng grass oral liquid.
15. The ginseng grass composition for use according to any one of claims 1 to 14.
16. A method for preparing the Shenlingcao oral liquid in the use described in claim 14, It is characterized in that The following steps are involved: (1) Take Ganoderma lucidum, Panax ginseng of the Araliaceae family, Cordyceps sinensis and rose, decoct them 2-3 times with 8-12 times the weight of water, collect the filtrate, concentrate it, and centrifuge it to obtain the supernatant; (2) The supernatant obtained in step (1), maltitol, cyclodextrin, American ginseng essence and water are mixed to obtain Shenlingcao oral liquid.
17. The preparation method according to claim 16, It is characterized in that The volume ratio of the total mass of the Ganoderma lucidum, the Araliaceae Panax genus medicinal materials, Cordyceps sinensis and rose flowers described in step (1) to the prepared Ganoderma lucidum oral liquid is 0.5-4:20 (g:mL).
18. Shenlingcao oral liquid prepared by the preparation method according to any one of claims 16-17.
Citation Information
Patent Citations
Traditional Chinese medicine composition for adjuvant therapy of COVID-19 severe cases
CN111991543A
Compositions and methods to relieve chronic diseases symptoms
US20170239305A1
